Autologous Dendritic Cell Vaccines in Lung Cancer

Completed

• Conditions: Cancer; on-Small Lung Cancer; Non-Small Lung Cancer

• Registration Number: ISRCTN45563569
• Lead Sponsor: ational Council of Scientific and Technological Development (CNPq) (Brazil)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-02-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

1. Histopathologically confirmed diagnosis of advanced NSCLC (stage IIIB-IV)
2. Age less than or equal to 70 years
3. Performance status less than or equal to 2
4. No prior chemotherapy, surgery, or radiotherapy
5. No central nervous system metastases
6. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria
7. No associated acute disease
8. HLA-A2 phenotype
9. Expression of Wilms Tumor Protein (WT1), Human Epidermal Growth Factor Receptor 2 (HER-2), Carcinoembryonic Antigen (CEA) or Melanoma Antigen 1 (MAGE1) proteins at the tumor site (tissue)

Exclusion Criteria

Progressive disease after conventional treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified